Below is our list of Senior Researchers.
Hilary works on the SmartNanoTox project, which focuses determining the toxicity of inhaled nanoparticles and establishing a system for classing new nanoparticles based on their ability to produce the pathway-relevant key event.
I am working on 3D co-culture of ovarian cancer cells with fibroblasts and immune cells to see how this effects chemosensitivity. These 3D cultures will be used in a microfluidic chip system in order to highthroughput screen for synergistic chemotherapy combinations in ovarian cancer patient samples.
My research is focused on investigating the crosstalk between proteins involved in epigenetic regulation of gene expression, and those involved in signalling pathways frequently altered in melanoma. In particular, I am interested in studying how this crosstalk may facilitate acquired drug resistance, and how inhibition of specific epigenetic machinery might abrogate this resistance.
Aleksanders work focuses on the interpretation of genomics data in the childhood malignancy neuroblastoma and on identifying novel signalling vulnerabilities as well as leads for future therapies. He is currently engaged with the melanoma research project and the investigation of resistance mechanisms to Raf targeting chemotherapeutics.
My research project is focused on the study of the pathogenesis of childhood cancer, identifying prognostic markers and novel therapeutic targets in MYC/MYCN-driven neuroblastoma by using -omics and systems biology approaches.
Adam is investigating (a) the mechanisms of drug resistance and design personalised drug combinations that can avoid or overcome this resistance; and (b) predict which drug combinations will be most effective for individual patients.